Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)
Move your mouse over image or click to enlarge

Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)

Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
Cat# Size Price Qty Buy
A2697-1mg*25 1mg*25
£2,432.00
A2697-1mg*5 1mg*5
£794.00
A2697-1mg 1mg
£303.00

Additional Information

Property Value or Rating
Manufacturer Selleck Chemicals LLC
Manufacturer Cat# A2697

Related Documents